Researchers from Mount Sinai School of Medicine have identified a mechanism controlling the function of a protein that binds to DNA during embryonic development and may function to prevent abnormal tumor growth. When the protein, TCF3, is modified by a small molecule called a phosphate, it no longer binds DNA, changing the way the protein signals during development. This discovery identifies a new diagnostic marker (phosphorylated TCF3) that may be associated with cancer and could represent a potential drug target.
Body
PROVIDENCE, R.I. [Brown University] — Mad Cow disease and its human variant Creutzfeldt—Jakob disease, which are incurable and fatal, have been on a welcome hiatus from the news for years, but because mammals remain as vulnerable as ever to infectious diseases caused by enigmatic proteins called prions, scientists have taken no respite of their own. In the Oct.
LIVERMORE, Calif. – Beta cells, which make insulin in the human body, do not replicate after the age of 30, indicating that clinicians may be closer to better treating diabetes.
Type 1 diabetes is caused by a loss of beta cells by auto-immunity while type 2 is due to a relative insufficiency of beta cells. Whether beta cells replicate after birth has remained an open issue, and is critically important for designing therapies for diabetes.
Montreal, October 28, 2010 – A team of scientists at the Institut de recherches cliniques de Montréal (IRCM) led by Dr. Jean-François Côté, Director of the Cytoskeletal Organization and Cell Migration research unit, identified a novel molecular mechanism in the control of cell motility. Their findings were published online today in Current Biology, a journal from the Cell Press group. This scientific breakthrough could eventually lead to the development of new cancer-treating drugs that could block the spread of tumours (metastasis).
La Jolla, CA, October 28, 2010 – For Immediate Release – A group of researchers at The Scripps Research Institute and the Scripps Translational Science Institute has published a paper that reviews new strategies for identifying collections of rare genetic variations that reveal whether people are predisposed to developing common conditions like diabetes and cancer.
BOSTON – The discovery that a protein called Rictor plays a key role in destroying a close cousin of the AKT oncogene could provide scientists with a new molecular target for treating certain cancers, including breast cancer. Described in the September 2010 issue of the journal Molecular Cell, the study was led by scientists at Beth Israel Deaconess Medical Center (BIDMC).
PHILADELPHIA — An investigational DNA methylation test could alter the screening landscape for colorectal cancer, according to data presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held here Oct. 27-30, 2010.
PHILADELPHIA — For the first time, researchers have found a link between long telomeres and an increased risk for colorectal cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held here Oct. 27-30, 2010.
PHILADELPHIA — A variant site linked to poor outcome in advanced colorectal cancer has now been found to predict improved prognosis in early stages of cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
PHILADELPHIA — University of Pittsburgh researchers have devised a three-dimensional system in laboratory culture that mimics the growth patterns of colon cancer stem cells in patients. Their findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
CAMBRIDGE, Mass. -- In a study of mice with lymphoma, MIT biologists have discovered that a small number of cancer cells escape chemotherapy by hiding out in the thymus, an organ where immune cells mature. Within the thymus, the cancer cells are bathed in growth factors that protect them from the drugs' effects. Those cells are likely the source of relapsed tumors, said Michael Hemann, MIT assistant professor of biology, who led the study.
Many times, cancer patients respond very well to chemotherapy initially only to have their disease return, sometimes years later. Now researchers reporting in the October 29th issue of the journal Cell, a Cell Press publication, have new insight into the factors that allow some lingering tumor cells to resist treatment and to seed that kind of resurgence.
White blood cells called neutrophils are part of the body's first line of defense against bacterial infection. Neutrophils are recruited from the bloodstream to infected tissues where they release powerful chemicals that kill bacteria and amplify the immune response. These cells function as first responders at the scene of infection and often have a short life span. As a result, new neutrophils are produced continuously from stem cells in the bone marrow. Previous research has suggested that regulation of neutrophil production is a complex and carefully controlled process.
Countless people clung to life in the branches of trees hemming the shorelines during the deadly 2004 tsunami that killed more than 230,000 coastal residents in Indonesia, India, Thailand and Sri Lanka. In the aftermath of the disaster, land change scientist Chandra Giri from the U.S. Geological Survey (USGS) decided to explore to what degree those unique trees – which make up valuable forest ecosystems called mangroves -- safeguard lives, property and beaches during hurricanes, tsunamis and floods.